BioVectra to Manufacture Helix’ Lung Cancer Candidate
Company one of largest producers in North America for urease substance, which is a core part of L-DOS47.!--h2>
Helix BioPharma signed an agreement with BioVectra to manufacture L-DOS47 bulk drug product for clinical testing in patients with adenocarcinoma of the lung. "BioVectra is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product," notes John Docherty, Helix' vp of corporate development.
During 2007, Helix intends to complete the remaining preclinical animal testing work with L-DOS47, in parallel with finalizing its clinical manufacturing activities.